WuXi Biologics (Cayman) Inc. (02269.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.2x

Market Cap

HKD 198.07B

MomentumView details →

1D Return

−3.00%

YTD Return

+56.42%

RSI (14)

58.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.2x

Market Cap

HKD 198.07B

RSI (14)

58.2

MomentumView details →

1D Return

−3.00%

YTD Return

+56.42%

ProfitabilityView details →

Gross Margin

45.25%

Net Margin

21.15%

EBITDA Margin

37.25%

ROE (TTM)

19.15%

ROA (TTM)

14.09%

Asset Turnover

0.67x

GrowthView details →

Revenue YoY

+29.24%

EPS YoY

+42.58%

FCF YoY

+489.48%

Revenue CAGR 3Y

+12.59%

EPS CAGR 3Y

+3.05%

EBITDA YoY

+71.92%

EarningsView details →

EPS (Actual)

HKD 0.67

EPS Surprise

28.90%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

28.90%

Rev Surprise

2.65%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

3.04x

Quick Ratio

2.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

43.52B

Net Income (TTM)

9.21B

Op. CF (TTM)

10.32B

Next earningsMar 23, 2027 →

Latest newsMore news →

WuXi Biologics management raised its full-year 2026 revenue growth guidance to 20%-23% year-over-year on a constant currency basis, up from the previous 16%-20% guidance.9d ago

WuXi Biologics reported first-half results with revenue up 18.4% year-on-year to RMB 11.787 billion, gross profit up 28.1% to RMB 5.448 billion, and net profit up 5.8% to RMB 2.916 billion.11d ago

Similar companies

Green Cross Holdings Corporation005257.KS EASY BIO,Inc.353810.KQ BINEX Co., Ltd.053030.KQ HLB Therapeutics Co.,Ltd.115450.KQ JETEMA, Co., Ltd.216080.KQ GC Cell Corporation144510.KQ Find similar companies →

Latest newsMore news →

WuXi Biologics management raised its full-year 2026 revenue growth guidance to 20%-23% year-over-year on a constant currency basis, up from the previous 16%-20% guidance.9d ago WuXi Biologics reported first-half results with revenue up 18.4% year-on-year to RMB 11.787 billion, gross profit up 28.1% to RMB 5.448 billion, and net profit up 5.8% to RMB 2.916 billion.11d ago Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.29d ago